INVESTIGATOR INITIATED TRIALS IN THE WILD, WILD WEST:
Implementation of the Oncology Clinical Research Support Team at the University of Colorado Cancer Center

BACKGROUND: Investigator Initiated Trial (IIT) accruals lagged below targets for the CU Cancer Center and were a critique from NCI during CCSG site visit. In order to improve chances of success for IITs, a central support office (Oncology Clinical Research Support Team – OCRST) was established in 2015 to provide regulatory expertise, clinical project coordination, and data monitoring for interventional IITs.

GOALS of the central office included:
- Increase IIT accruals for CCSG competitive renewal
- Reduce burden to clinical trials office in managing FDA submissions and project coordination
- Develop infrastructure necessary to conduct high quality investigations including provision of clinical data monitoring

METHODS:
- Establish IIT Incubator and IIT Feasibility Review/Approval
- OCRST team of regulatory, clinical and monitoring experts
- OCRST team
- IIT specific protocol templates
- Multicenter project assessment
- Case Report Form development
- Clinical monitoring
- SOPs and Guidance document development

RESULTS/CONCLUSIONS:
- Accruals to IITs increased by 6x since 2016
- Increase number of active trials from 5 in 2016 to 46 in 2020
- >30 active interventional IITs; 10 with INDs; 13 multisite trials
- Implemented IIT specific SOPs and Guidance documents
- Increased OCRST dedicated resources from 6 FTEs in 2016 to 14 FTEs in 2020
- Implemented fee schedule to secure revenue on externally funded projects for OCRST services
- Leveraged UCCC funding support paired with industry and philanthropy to support IITs
- Conducted 161 monitoring visits in CY2019

FUTURE DIRECTIONS/LESSONS LEARNED:
- Volume and complexity of projects much higher than was first envisioned, multiple amendments
- IIT scoring being implemented to align approval with CC strategic plan
- Monitoring team underway to implement risk based/targeted monitoring approach for most requested resources
- OCRST developed tools and processes to minimize amendments, enhance protocol review, interim/safety analysis, and study closeout
- Implement electronic solutions to improve efficiency (ECRF, e-监管平台)

FUNDING: LEVERAGING UCCC INVESTMENT

$17.5M Total
$0.9M Cancer League
$5.7M Investigator- Controlled Funds

$4.6M UCCC Investment
$10.9M Industry Funding

IIT Trials Open and Accruals FY16-20 (projected)

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Trials Open</th>
<th>Inst'l Accruals</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>5</td>
<td>34</td>
</tr>
<tr>
<td>2017</td>
<td>15</td>
<td>131</td>
</tr>
<tr>
<td>2018</td>
<td>29</td>
<td>184</td>
</tr>
<tr>
<td>2019</td>
<td>39</td>
<td>209</td>
</tr>
<tr>
<td>2020</td>
<td>46</td>
<td>170</td>
</tr>
</tbody>
</table>